Color vision and contrast sensitivity in epilepsy patients treated with initial tiagabine monotherapy.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Epilepsy Research

• Publication date

  2005-12-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/J.EPLEPSYRES.2005.09.002PMID 16257182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of antiepileptic drugs on visual performance.

  2004cited by this paper
• Normal test scores in the Farnsworth–Munsell 100 hue test

  2004cited by this paper
• Color vision in epileptic adolescents treated with valproate and carbamazepine.

  2004cited by this paper
• A controlled study comparing visual function in patients treated with vigabatrin and tiagabine

  2003cited by this paper
• Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.

  2003cited by this paper
• Viagra (sildenafil citrate) and ophthalmology.

  2002cited by this paper
• Visual fields and tiagabine: a quandary.

  2001cited by this paper
• Changes in Color Vision after a Single Dose of Vigabatrin or Carbamazepine in Healthy Volunteers

  2001cited by this paper
• Visual field constriction

  2001cited by this paper
• Normal values for the Pelli‐Robson contrast sensitivity test

  2001cited by this paper
• Normal test scores in the Farnsworth-Munsell 100 hue test.

  2001cited by this paper
• COLOR VISION DEFECTS AFTER CENTRAL SEROUS CHORIORETINOPATHY

  2000cited by this paper
• Visual Function in Patients Treated with the GABAergic Anticonvulsant Drug Tiagabine

  2000cited by this paper
• Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy.

  2000cited by this paper
• Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers

  2000cited by this paper
• Safety of tiagabine: summary of 53 trials.

  1999cited by this paper
• Assessment of Colour Vision in Epileptic Patients Exposed to Single-Drug Therapy

  1999cited by this paper
• Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects

  1999cited by this paper
• Vigabatrin-associated retinal cone system dysfunction

  1998cited by this paper
• A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Northern European Tiagabine Study Group.

  1998cited by this paper
• A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures

  1998cited by this paper
• Severe persistent visual field constriction associated with vigabatrin

  1997cited by this paper
• Color vision tests for early detection of antiepileptic drug toxicity

  1997cited by this paper
• Tiagabine Monotherapy in the Treatment of Partial Epilepsy

  1995cited by this paper
• A Review of the Preclinical Pharmacology of Tiagabine: A Potent and Selective Anticonvulsant GABA Uptake Inhibitor

  1995cited by this paper
• The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats.

  1992cited by this paper
• THE DESIGN OF A NEW LETTER CHART FOR MEASURING CONTRAST SENSITIVITY

  1988cited by this paper
• RELIABILITY AND SENSITIVITY OF CLINICAL CONTRAST SENSITIVITY TESTS

  1988cited by this paper
• Standard Pseudoisochromatic Plates part 2.

  1985cited by this paper
• Color-axis determination on the Farnsworth-Munsell 100-hue test.

  1985cited by this paper
• A new assessment of the normal ranges of the Farnsworth-Munsell 100-hue test scores.

  1982cited by this paper
• THE FARNSWORTH-MUNSELL 100-HUE TEST*

  1971cited by this paper
• Proposals for scoring and assessing the 100-Hue test.

  1970cited by this paper

• Transport and inhibition mechanism for human TauT-mediated taurine uptake

  2025cites this paper
• Albumin host for supramolecular fluorescence recognition.

  2024cites this paper
• Human Serum Albumin-Occupying-Based Fluorescence Turn-On Analysis of Anti-epileptic Drug Tiagabine Hydrochloride.

  2020cites this paper
• Additional options for non-pharmacological treatment of epilepsy

  2019cites this paper
• Ocular dysfunctions and toxicities induced by antiepileptic medications: Types, pathogenic mechanisms, and treatment strategies

  2019cites this paper
• An investigation to determine the influence of illumination sources on colour discrimination in normal subjects and smokers

  2015cites this paper
• Ocular Adverse Effects Associated with Systemic Medications

  2012cites this paper
• Visual contrast sensitivity in tonic-clonic epileptic patients

  2011cites this paper
• Tiagabine: efficacy and safety in partial seizures – current status

  2008cites this paper
• [Synchronized, oscillatory brain activity in visual perception].

  2008cites this paper
• The effect of age‐related lens yellowing on Farnsworth–Munsell 100 hue error score

  2008cites this paper
• CNS Adverse Events Associated with Antiepileptic Drugs

  2008cites this paper
• Antiepileptic drugs and visual function.

  2007cites this paper
• Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII).

  2007cites this paper
• Ocular adverse effects associated with systemic medications : recognition and management.

  2007cites this paper